BIOTHERAPEUTICS AND BIOCOMPATIBLE DRUG DELIVERY SYSTEMS
- Academic year
- 2021/2022 Syllabus of previous years
- Official course title
- BIOTHERAPEUTICS AND BIOCOMPATIBLE DRUG DELIVERY SYSTEMS
- Course code
- PHD116 (AF:359835 AR:188302)
- On campus classes
- ECTS credits
- Degree level
- Corso di Dottorato (D.M.45)
- Educational sector code
- 2nd Semester
- Course year
- Go to Moodle page
Contribution of the course to the overall degree programme goals
Expected learning outcomes
The aim of module B ("Biocompatible drug delivery systems") is to provide the students with the knowledge on the applications of bionanomaterials to cancer therapy. The students are guided in the understanding of the actual strategies to deliver chemo- and targeted-therapies in cancer patients by mean of nanomaterials. Analysing the history of chemo- and target-therapies together with drug delivery, the students acquire the rationale of the key steps pursued by scientists to overcome actual biological barriers and the misunderstanding and pitfalls that are still there.
• Peptide therapeutics: advantages and disadvantages. Natural product derived peptides as starting points for drug discovery. Display technologies in peptide lead discovery: phage display, mRNA display and ribosome display. Stapled peptides. Strategies to extend the half-life of peptides;
• Cytokine-based therapies: benefits and limitations. Interleukins approved for therapy. Engineering and synthetic cytokines signalling for therapeutics.
• Non-antibody scaffold drugs: advantages and major challenges. Strategies for the generation of differentiated non-antibody scaffold drugs. Examples of non-antibody scaffold molecules for therapeutic, diagnostic and biotechnological applications.
• Therapeutic antibodies: properties and mode of actions. Multidimensional engineering of antibodies: antigen binding, Fc receptor binding and modularity. Multispecific antibodies. Antibody fragments. Antibody drug conjugates (ADCs).
• Cell-based therapies. Adoptive cell therapy using tumour-infiltrating lymphocytes (TIL). Engineered T cell expressing chimeric antigen receptors (CAR-T). Therapeutic approaches to enhance natural killer (NK) cell cytotoxicity against cancer. Macrophages in immunotherapy. Engineering stem cells for cancer therapy. Dendritic cell (DC) in cancer immunotherapy. Antigen-specific therapeutic approaches for autoimmunity. Red blood cell-based therapies.
• Nucleic acid therapeutics: advantages and disadvantages. Principle of systematic evolution of ligands by exponential enrichment (SELEX). DNA, RNA aptamers. Antisense oligonucleotide (AON). RNA interference (RNAi). Ribozymes.
Contents of module B include:
• Chemotherapy - a historical overview with examples focused on the development and application of nitrogen mustard, folic acid, vinca alkaloids, taxanes and cisplatin.
• Target therapies - the development and application of imatinib, gefitinib and bevacizumab.
• Hallmarks of cancers - an analysis of the principles which govern cancer complexity: sustaining proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming energy metabolism and evading immune destruction.
• Barriers in drug delivery - principles of nanomedicine and the biological barriers: passive against active targeting, the mononuclear phagocyte system, nonspecific distribution of nanoparticles, hemorheological limitations, intratumoral pressure, cell membrane internalization, endosomal escape and multi drug resistance mechanisms.
• Misunderstandings and pitfalls - common mistakes and underestimations in nanoparticle testing: nanoparticles extravasation, tissue penetration and formulation; difference between mouse models and human; approaches to metastatic cancer; personalized therapy.
• Doxil, a history of success - rational for the development of a liposomal drug: slow drug release, site avoidance, accumulation in the tumor, protein binding, RES clearance, glomerular filtration, microvasculature permeability, extravascular transport; stealth technology and remote loading; applications in clinic.
• CRISPR/CAS9 technology – a historical overview; bacterial CRISPR-CAS systems; CRISPR technology in human; Applications and limitations in cancer.
STRUCTURE AND CONTENT OF THE COURSE COULD CHANGE AS A RESULT OF THE COVID-19 EPIDEMIC.
Accommodation and support services for students with disabilities and students with specific learning impairments: Ca’ Foscari abides by Italian Law (Law 17/1999; Law 170/2010) regarding support services and accommodation available to students with disabilities. This includes students with mobility, visual, hearing and other disabilities (Law 17/1999), and specific learning impairments (Law 170/2010). In the case of disability or impairment that requires accommodations (i.e., alternate testing, readers, note takers or interpreters) please contact the Disability and Accessibility Offices in Student Services: email@example.com